LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.
-
Upload
justus-shipton -
Category
Documents
-
view
213 -
download
0
Transcript of LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.
![Page 1: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/1.jpg)
LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA
PROF L DE ROY UNIVERSITE DE LOUVAIN
BELGIQUE
![Page 2: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/2.jpg)
STROKE
Rate in patients not taking warfarin, in AF 5.00 / year 1.0 - 7.0
Rate in patients taking warfarin, in AF 1.35 / year 0.4 - 2.3
Rate in patients not taking warfarin, in NSR 0.1 / year 0.09 - 1.0
Relative risk for patients with previous stroke 2.0* 1.0 - 3.0*
Risk of death from stroke 25 8 - 35
Risk of permanent disability for survivors 50 35 - 71
Rate in patients not taking warfarin, in AF 0.80 / year 0 - 1.9
Rate in patients taking warfarin, in AF 1.46 / year 0.49 - 18.0
Relative risk for patients with previous bleed 1.5* 0 - 3.0*
Risk of death from major bleed 22 12.5 - 33
Risk of morbidity for survivors of major bleed 7 0 - 15
MAJOR BLEEDING EVENT
* integerGreenberg 1998Marcov Decision Analysis in AF
AF : STROKE AND BLEEDING EVENTS
![Page 3: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/3.jpg)
Stroke Prevention in Atrial Fibrillation: Warfarin Data
Warfarin BetterWarfarin Worse
Combined 108 3691
SPINAF 29 972
SPAF 23 508
CAFA 14 478
BAATAF 15 922
AFASAK 27 811
No. ofEvents
Patient-Years
100 50 0 -50 -100
Atrial Fibrillation Investigators. Arch Intern Med. 1994;154:1449-1457. RR: 69% (p<.001)
![Page 4: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/4.jpg)
Stroke Prevention in Atrial Fibrillation: ASA Data
Atrial Fibrillation Investigators. Arch Intern Med. 1994;154:1449-1457.
Aspirin Better Aspirin Worse
Risk Reduction, 19 %
Combined 100 2264
SPAF 65 1457
AFASAK 35 807
No. ofEvents
Patient-Years
100 50 0 -50 -100
![Page 5: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/5.jpg)
Antithrombotic therapy to prevent thromboembolism is recommended for ALL PATIENTS with AF,
except those with lone AF or contraindications.
Classe
I IIa IIb III
A
B
C
PREVENTION DES THROMBO-EMBOLIES CONCEPT GENERAL
Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
![Page 6: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/6.jpg)
THROMBOEMBOLISM RISK FACTORSTHROMBOEMBOLISM RISK FACTORS
Major Risk Factors: - Valvular heart disease- Prosthetic heart valve- Prior CVA or TIA
Moderate Risk Factors:- Age > 75- HTN- Diabetes- CHF
![Page 7: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/7.jpg)
Critères de risque CHADS2 Score
AVC ou AIT 2
Age > 75 ans 1
Hypertension 1
Diabète 1
Insuffisance cardiaque 1
CHADS2 : évaluation du risque d’AVC chez des patients avec FA non valvulaire
sans anticoagulation
![Page 8: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/8.jpg)
Patients(N=1733)
Risque ajusté d’AVCRatio (% / an)* (IC 95%)
ScoreCHADS2
120 1,9 (1,2 à 3,0) 0
463 2,8 (2,0 à 3,8) 1
523 4,0 (3,1 à 5,1) 2
337 5,9 (4,6 à 7,3) 3
220 8,5 (6,3 à 17,5) 4
65 12,5 (8,2 à 17,5) 5
5 18,2 (10,5 à 27,4) 6
* Le ratio ajusté d’AVC est dérivé d’une analyse multivariée ne comportant pas d’usage d’aspirine.
Relation entre le score de CHADS2et le risque d’AVC
Arch Intern Med 2003;163:936–43JAMA 2001;285:2864 –70
![Page 9: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/9.jpg)
For primary prevention of thromboembolism in patients with nonvalvular AF who have just
ONE of the MODERATE validated risk factors,
antithrombotic therapy with either ASPIRIN OR A VITAMIN K antagonist is reasonable,
Classe
I IIa IIb III
A
B
C
PREVENTION DES THROMBO-EMBOLIES ASPIRINE OU AVK ?
![Page 10: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/10.jpg)
Anticoagulation with a vitamin K antagonist is recommended for patients
with >1 MODERATE RISK FACTOR
Such factors include age over 75 years or greater, hypertension, heart failure, impaired left ventricular systolic function (ejection fraction 35% or less or fractional shortening less than 25%), and diabetes mellitus.
Classe
I IIa IIb III
A
B
C
PREVENTION DES THROMBO-EMBOLIES INDICATION DES ANTICOAGULANTS ORAUX
![Page 11: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/11.jpg)
For patients with nonvalvular AF who have one or more of the following less well-validated risk factors, antithrombotic therapy with either ASPIRIN OR A VITAMIN K ANTAGONIST is reasonable for
prevention of thromboembolism: age 65 to 74 years, female gender or coronary artery disease. The choice of agent should be based upon the risk of bleeding complications, ability to safely sustain adjusted chronic anticoagulation, and patient preferences.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Prévention des thrombo-embolies FACTEURS DE RISQUE MOINS VALIDES
![Page 12: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/12.jpg)
1.0
Odd ratio
Accidents ischémiques
Hémorragies intracraniennes
20
15
10
5
1
2.0 3.0 4.0 5.0 6.0 7.0 8.0
International Normalized Ratio
RISQUE D’HÉMORRAGIE INTRACRANIENNE SELON L’INTENSITÉ DE L’ANTICOAGULATION
![Page 13: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/13.jpg)
Long-term anticoagulation with a vitamin K antagonist
IS NOT RECOMMENDED
for primary prevention of stroke in patients
≤ 60 years
without heart disease (lone AF)
or risk factors for thromboembolism.
Classe
I IIa IIb III
A
B
C
PREVENTION DES THROMBO-EMBOLIES LONE AF + AVK
ACC/AHA/ESC Guidelines Circulation 2006
![Page 14: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/14.jpg)
In patients with AF < 60 years without heart disease or risk factors for thromboembolism (lone AF),
the risk of thromboembolism is low without treatment and the effectiveness of aspirin for primary prevention of stroke relative to the risk of bleeding
has not been established.
Classe
I IIa IIb III
A
B
C
PREVENTION DES THROMBO-EMBOLIES LONE AF + ASPIRINE
![Page 15: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/15.jpg)
STENTS + FA
![Page 16: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/16.jpg)
Clopidogrel should be given for a minimum of 1 month after implantation of a bare metal stent, at least 3 months for a sirolimus-eluting stent, at least 6 months for a paclitaxel-eluting stent and 12 months or longer in selected patients, following which warfarin may be continued as monotherapy in the absence of a subsequent coronary event.
When warfarin is given in combination with clopidogrel or low-dose aspirin, the dose intensity must be carefully regulated.
Classe
I IIa IIb III
A
B
C
PREVENTION DES THROMBO-EMBOLIES STENTS
![Page 17: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/17.jpg)
STENTS ANTIPLAQUETTAIRES ET AVKCONSENSUS
1.BMS: AAS: à vie
CLOPIDOGREL 75 mg: 1 mois
2. DES: AAS + CLOPIDOGREL: 1 an
AAS + CLOPIDOGREL: à vie (si haut risque)
3. INFARCTUS : AAS + CLOPIDOGREL: 1 an
![Page 18: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/18.jpg)
STENTS ET ANTIAGREGANTS
Guidelines for PCI EurHJ 2005
![Page 19: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/19.jpg)
Rubboli Expert consensus document Ann Med 2008
HEMORRAGIES MAJEURES ET TRIPLE THERAPIE
![Page 20: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/20.jpg)
QUID DES ANTIAGREGANTS?
![Page 21: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/21.jpg)
ETUDE ACTIVE(BMS / Sanofi-Synthelabo)
FA documentéeFacteurs de risques cardio-vasculaires
Eligible pour ACTIVE W :
Clopidogrel (75 mg) + Aspirine (75 à 100 mg)versus
Anticoagulant oral standard avec ajustement de la dose
Eligible pour ACTIVE A :
Clopidogrel (75 mg) + Aspirine (75 à 100 mg)versus
Aspirine (75 à 100 mg) (double aveugle)
ACTIVE I :
Irbesartan versus Placebo (double aveugle)
Follow-up : 3 ans(visites tous les 3 mois puis tous les 6 mois)
Facteurs influençant le choix pour ACTIVE A
![Page 22: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/22.jpg)
Connoly Lancet 2006
ACTIVE W
![Page 23: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/23.jpg)
Hohnloser ACTIVE W JACC 2007
![Page 24: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/24.jpg)
Healey ACTIVE: Risks and benefit Stroke 2008
ACTIVE + RISK FACTORS
![Page 25: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/25.jpg)
Hohnloser ACTIVE W JACC 2007
n: 6706 pts
![Page 26: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/26.jpg)
The Cochrane library 2008
![Page 27: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/27.jpg)
The Cochrane library 2008
![Page 28: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/28.jpg)
Aspirin, 81-325 mg daily, is recommended as an alternative to vitamin K antagonists in low-risk patients or in those with contraindications to oral anticoagulation.
Classe
I IIa IIb III
A
B
C
Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Prévention des thrombo-embolies ASPIRINE
![Page 29: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/29.jpg)
For patients with AF who have mechanical heart valves, the target intensity of anticoagulation should be based on the type of prosthesis maintaining a INR of at least 2.5.
Classe
I IIa IIb III
A
B
C
Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Prévention des thrombo-embolies VALVES MECANIQUES
![Page 30: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/30.jpg)
Antithrombotic therapy is recommended for patients with atrial flutter as for those with AF.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Prévention des thrombo-embolies FLUTTER AURICULAIRE
![Page 31: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/31.jpg)
In patients with AF who do not have mechanical prosthetic heart valves, it is reasonable to interrupt anticoagulation for up to one week without substituting heparin for surgical or diagnostic procedures that carry a risk of bleeding.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Prévention des thrombo-embolies AVK ET INTERVENTION A RISQUE HEMORRAGIQUE
![Page 32: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/32.jpg)
PATIENTS AGES?
![Page 33: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/33.jpg)
n: 973 ptsMean age: 81.5 y
BAFTA STUDY
ELDERLY
![Page 34: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/34.jpg)
In patients 75 years of age and older at increased risk of bleeding but without frank contraindications to oral anticoagulant therapy, and in other patients with moderate risk factors for thromboembolism who are unable to safely tolerate anticoagulation at the standard intensity
of INR 2.0 to 3.0, a LOWER INR TARGET OF 2.0 (range 1.6 to 2.5) may be considered for primary prevention of ischemic stroke and systemic embolism.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Prévention des thrombo-embolies AVK A DOSE MODEREE?
![Page 35: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/35.jpg)
ET POUR LA CARDIOVERSION?
![Page 36: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/36.jpg)
During the first 48 hours after onset of AF, the need for anticoagulation before and after cardioversion may be based on the patient’s risk of thromboembolism.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Anticoagulation pour la cardioversionAVK ET FA < 48 h
![Page 37: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/37.jpg)
As an alternative to anticoagulation prior to cardioversion of AF, it is reasonable to perform transesophageal echocardiography (TEE) in search of thrombus in the left atrium or left atrial appendage.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Anticoagulation pour la cardioversionCARDIOVERSION RAPIDE
![Page 38: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/38.jpg)
For patients with no identifiable thrombus, CARDIOVERSION is reasonable immediately after anticoagulation with UNFRACTIONATED HEPARIN (e.g., initiate by intravenous bolus injection and an infusion continued at a dose adjusted to prolong the activated partial thromboplastin time to 1.5 to 2 times the control value until oral anticoagulation has been established with a vitamin K antagonist (e.g., warfarin), as evidenced by an INR ≥ 2.0.).
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Anticoagulation pour la cardioversionCARDIOVERSION RAPIDE
![Page 39: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/39.jpg)
Thereafter, oral anticoagulation (INR 2.0 to 3.0) is reasonable for a total anticoagulation period of at least 4 weeks, as for patients undergoing elective cardioversion.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Anticoagulation pour la cardioversionCARDIOVERSION RAPIDE
![Page 40: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/40.jpg)
Limited data are available to support the subcutaneous administration of a low-molecular-weight heparin in this indication.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Anticoagulation pour la cardioversionCARDIOVERSION RAPIDE
![Page 41: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/41.jpg)
ACUTE II TRIAL KLEIN 2006
![Page 42: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/42.jpg)
For patients with atrial flutter undergoing cardioversion, anticoagulation can be beneficial according to the recommendations as for patients with AF.
Classe
I IIa IIb III
A
B
C Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. 2006 Sep;8(9):651-745.
Anticoagulation pour la cardioversionFLUTTER AURICULAIRE
![Page 43: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/43.jpg)
Targets for Antithrombotic treatment in atrial fibrillation
Tissue factor
Plasma Clotting Cascade
Prothrombin
Factor Xa
Thrombin
Fibrinogen
Collagen
ADP
Thromboxane A2
Conformational Activation of GPIIb/IIIa
Platelet Aggregation
Thrombus
Fibrin
ApixabanApixabanRivaroxabanRivaroxaban
IdraparinuxIdraparinuxAT
DabigatranDabigatranXimelagatranXimelagatran
AspirinAspirin
ClopidogrelClopidogrelPrasugrelPrasugrelAZD6140AZD6140CangrelorCangrelor
![Page 44: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/44.jpg)
RE-LY TRIAL
18.114 pts
DABIGATRAN ETEXILATE vs WARFARINE (INR 2-3)
ARISTOTLE TRIAL
APIXABAN vs WARFARINE
![Page 45: LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.](https://reader030.fdocuments.us/reader030/viewer/2022032517/56649c815503460f949397d9/html5/thumbnails/45.jpg)
CONCLUSIONS
1. Un traitement antithrombotique doit toujours être envisagé chez un patient en FAP, persistante ou permanente.
2. Une sélection judicieuse des patients et de l’antithrombotique s’impose néanmoins .
3. L’abstention est parfois recommandée.
4. Les nouveaux anticoagulants oraux sont attendus avec impatience